MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

TAS6417

CAS No. : 1661854-97-2

MCE 站：TAS6417

产品活性：TAS6417 (CLN-081) 是高效的、具有口服活性的、广泛的 EGFR 突变型的抑制剂，可独特的结合到 EGFR 铰链区的 ATP 结合位点，其 IC₅₀ 值为 1.1-8.0 nM。

研究领域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK  |  Apoptosis

作用靶点：EGFR  |  Apoptosis

In Vitro: TAS6417 inhibits EGFR phosphorylation ａnd downstream molecules in NSCLC cell lines expressing EGFR exon 20 insertions, resulting in caspase activation.
TAS6417 is a robust inhibitor against the most common EGFR mutations (exon 19 deletions ａnd L858R) ａnd the most potent against cells harboring EGFR-T790M (1st/2nd generation TKI resistance mutation).
TAS6417 covalently modified the cysteine residue at position 797 of recombinant EGFR harboring an in-frame insertion mutation in the exon 20 region.
TAS6417 inhibits EGFR signal transduction, leading to cell growth inhibition ａnd apoptosis induction in NSCLC cells driven by EGFR exon 20 insertion mutations.
TAS6417 (0-10 μM) inhibits cell proliferation ａnd EGFR signaling in NSCLC cell lines harboring EGFR common mutations in the presence or absence of T790M.

In Vivo: TAS6417 (10-200 mg/kg) causes persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models. TAS6417 inhibits mutant EGFR in tumors but not WT EGFR in skin tissues.
TAS6417 had no effect on EGFR-independent proliferation in NCI-H23 or NCI-H460 cells.
TAS6417 administered at 20 mg/kg, which achieves complete suppression of tumor growth, induces a significant decrease in pEGFR, leading to reduction of pAKT ａnd pERK at 1 h. The inhibitory effect is still noted at 6 h, ａnd phosphorylation of EGFR, ATK, ａnd ERK recovered by 24 h.
TAS6417 (100 ａnd 200 mg/kg/day) prolongs survival of animals bearing lung cancer.

相关产品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Covalent Screening Library  |  Differentiation Inducing Compound Library  |  Orally Active Compound Library  |  Anti-Hepatitis C Virus Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  MG-132  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Paclitaxel  |  Y-27632 dihydrochloride  |  Angiotensin II human  |  Acetylcysteine  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Bortezomib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Gemcitabine  |  Verteporfin  |  Temozolomide  |  Decitabine  |  Gefitinib  |  BAY 11-7082  |  Etoposide  |  CCCP  |  DAPT  |  Rote  |  Etomoxir  |  Trastuzumab  |  Stattic  |  Docetaxel  |  Fulvestrant

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。